Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02515331 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
A Phase 2 study of Patients, Resistant Hypertension, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 16
- Study locations
NCT02515331: Completed Phase 2 study of Patients, Resistant Hypertension, sponsored by Novartis Pharmaceuticals.
NCT02515331 is a Phase 2 study of Patients, Resistant Hypertension that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 64 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (52% lower). The trial reports 16 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02515331, a Phase 2 study of Patients, Resistant Hypertension, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of the present study was to determine whether LHW090 displays the clinical safety and efficacy profile to support further development in patients with resistant hypertension.
Primary Outcome
Number of participants with AEs, SAEs and deaths were assessed.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LHW090
Study Locations (16)
Other
- Novartis Investigative Site - Gentofte Municipality
- Novartis Investigative Site - Paris
- Novartis Investigative Site - Berlin
- Novartis Investigative Site - Düsseldorf
- Novartis Investigative Site - Hanover
- Novartis Investigative Site - Homburg
- Novartis Investigative Site - Basel
- Novartis Investigative Site - Lausanne
Florida
- Novartis Investigative Site - Atlantis
- Novartis Investigative Site - Daytona Beach
- Novartis Investigative Site - Jacksonville
Alabama
- Novartis Investigative Site - Birmingham
California
- Novartis Investigative Site - North Hollywood
Hawaii
- Novartis Investigative Site - Honolulu
Tennessee
- Novartis Investigative Site - Knoxville
Netherlands
- Novartis Investigative Site - Meibergdreef 9
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2015-11-04 |
| Est. Completion | 2017-08-17 |
| Phase | Phase 2 |
What the finished NCT02515331 record still lists
NCT02515331 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Patients, Resistant Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02515331 lists 16 locations in 7 states (Other, Florida, Alabama).
Frequently Asked Questions
What is clinical trial NCT02515331 about?
NCT02515331 is a clinical study titled "Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients". The purpose of the present study was to determine whether LHW090 displays the clinical safety and efficacy profile to support further development in patients with resistant hypertension.
What is the current status of trial NCT02515331?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2015-11-04. Estimated completion is 2017-08-17.
What conditions does trial NCT02515331 study?
This clinical trial studies the following conditions: Patients, Resistant Hypertension.
What interventions are being tested in trial NCT02515331?
The interventions under investigation include: Placebo (DRUG), LHW090 (DRUG).
Who is sponsoring clinical trial NCT02515331?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02515331 being conducted?
This trial has 16 study locations across Alabama, California, Florida, Hawaii, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02515331's enrollment target sits among peer trials
64 996th of 2000 higher than 992 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI